Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21WAF1

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 4, 2006, Pages 183-191

  Okamoto, Hiroshi ^a   Fujioka, Yoshio ^a,b   Takahashi, Akihiro ^a   Takahashi, Tomosaburo ^a   Taniguchi, Takahiro ^a   Ishikawa, Yuichi ^c   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE GAKUIN UNIVERSITY   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Histone deacetylase; p21WAF1; Trichostatin A; Vascular smooth muscle cells

Indexed keywords

CDKN1A PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; PROTEIN SYNTHESIS INHIBITOR; THYMIDINE; TRICHOSTATIN A;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; MOUSE; MOUSE MUTANT; RAT; SMOOTH MUSCLE FIBER; THORACIC AORTA; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA, THORACIC; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; PROTEIN SYNTHESIS INHIBITORS; RATS; THYMIDINE;

EID: 33847227712     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.183     Document Type: Article

References (52)

1. Sherr CJ: G1 phase progression: cycling on cue. Cell, 1994; 79:551-555.
2. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med, 1999; 340:115-126.
3. Libby P: Inflammation in atherosclerosis. Nature, 2002; 420:868-874.
4. Draetta GF: Mammalian G1 cyclins. Curr Opin Cell Biol, 1994; 6:842-846.
5. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 1994; 79:573-582.
6. King RW, Jackson PK, and Kirschner MW: Mitosis in transition. Cell, 1994; 79:563-571.
7. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 1999; 13:1501-1512.
8. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell, 1993; 75:817-825.
9. Gu Y, Turck CW, and Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature, 1993; 366:707-710.
10. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 1994; 76:1013-1023.
11. Harper JW, Adami GR, Wei N, Keyomarsi K, and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell,1993; 75:805-816.
12. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature, 1993; 366:701-704.
13. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, and Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev, 1995; 9:935-944.
14. Hu PP, Shen X, Huang D, Liu Y, Counter C, and Wang XF: The MEK pathway is required for stimulation of p21 (WAF1/CIP1) by transforming growth factor-beta. J Biol Chem, 1999; 274:35381-35387.
15. Lee TH, Chuang LY, and Hung WC: Induction of p21WAF1 expression via SpI-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells. Oncogene, 2000; 19:3766-3773.
16. Takahashi A, Taniguchi T, Ishikawa Y, and Yokoyama M: Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21 (waf1/cip1/sdi1) and p53. Circ Res, 1999; 84:543-550.
17. Sata M, Takahashi A, Tanaka K, Washida M, Ishizaka N, Ako J, Yoshizumi M, Ouchi Y, Taniguchi T, Hirata Y, Yokoyama M, Nagai R, and Walsh K: Mouse genetic evidence that tranilast reduces smooth muscle cell hyperplasia via a p21 (WAF1)-dependent pathway. Arterioscler Thromb Vasc Biol, 2002; 22:1305-1309.
18. Rosato RR and Grant S: Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther, 2003; 2:30-37.
19. Gray SG and Teh BT: Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr Mol Med, 2001; 1:401-429.
20. Gray SG and Ekstrom TJ: The human histone deacetylase family. Exp Cell Res, 2001; 262:75-83.
21. Owen GI, Richer JK, Tung L, Takimoto G, and Horwitz KB: Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem, 1998; 273:10696-10701.
22. Billon N, Carlisi D, Datto MB, van Grunsven LA, Watt A, Wang XF, and Rudkin BB: Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene, 1999; 18:2872-2882.
23. Richon VM, Sandhoff TW, Rifkind RA, and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA, 2000; 97:10014-10019.
24. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, and Sakai T: Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem, 1997; 272:22199-22206.
25. Huang L, Sowa Y, Sakai T, and Pardee AB: Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene, 2000; 19:5712-5719.
26. Kim YB, Lee KH, Sugita K, Yoshida M, and Horinouchi S: Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 1999; 18:2461-2470.
27. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, and Nakanishi O: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA, 1999; 96:4592-4597.
28. Qiu P and Li L: Histone acetylation and recruitment of serum responsive factor and CREB binding protein onto SM22 promotor during SM22 gene expression. Circ Res, 2002; 90:858-865.
29. Noh EJ and Lee JS: Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition. Biochem Biophys Res Commun, 2003; 310:267-273.
30. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, and Sakai T: Sp3, but not Sp1, mediates the transcriptional activation of the p21/ WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res, 1999; 59:4266-4370.
31. Deng C, Zhang P, Harper JW, Elledge SJ, and Leder P: Mice lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 1995; 82:675-684.
32. Gunther S, Alexander RW, Atkinson WJ, and Gimbrone MA Jr: Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol, 1982; 92:289-298.
33. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, and Nabel EG: Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci USA, 1996; 93:7905-7910.
34. Rivero JA and Adunyah SE: Sodium butyrate stimulates PKC activation and induces differential expression of certain PKC isoforms during erythroid differentiation. Biochem Biophys Res Commun, 1998; 248:664-668.
35. Akashi M, Osawa Y, Koeffler HP, and Hachiya M: p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem J, 1999; 337(Pt 3):607-616.
36. Frey MR, Saxon ML, Zhao X, Rollins A, Evans SS, and Black JD: Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21 (waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J Biol Chem, 1997; 272:9424-9435.
37. Newton AC: Regulation of protein kinase C. Curr Opin Cell Biol, 1997; 9:161-167.
38. Li YJ, Laurent-Puig P, Salmon RJ, Thomas G, and Hamelin R: Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene, 1995; 10:599-601.
39. Xiao H, Hasegawa T, Miyaishi O, Ohkusu K, and Isobe K: Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner. Biochem Biophys Res Commun, 1997; 237:457-460.
40. Besson A and Yong VW: Involvement of p21 (Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression. Mol Cell Biol, 2000; 20:4580-4590.
41. Hollstein M, Sidransky D, Vogelstein B, and Harris CC: p53 mutations in human cancers. Science, 1991; 253:49-53.
42. Biggs JR, Kudlow JE, and Kraft AS: The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem, 1996; 271:901-906.
43. Adnane J, Bizouarn FA, Qian Y, Hamilton AD, and Sebti SM: p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol, 1998; 18:6962-6970.
44. Li H and Wu X: Histone deacetylase inhibitor, Trichostatin A, activates p21 WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun, 2004; 324:860-867.
45. Xiao H, Hasegawa T, and Isobe K: Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone dcacetylase inhibitor in NIH3T3 cells. J Cell Biochem, 1999; 73:291-302.
46. Huang N, Katz JP, Martin DR, and Wu GD: Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine, 1997; 9:27-36.
47. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, and Mascagni P: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA, 2002; 99:2995-3000.
48. Choi JH, Nam KH, Kim J, Back MW, Park JE, Park HY, Kwon HJ, Kwon OS, Kim DY, and Oh GT: Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2005; 25:2404-2409.
49. Gu W and Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 1997; 90:595-606.
50. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, and Schreiber SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA, 2003; 100:4389-4394.
51. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, and Yoshida M: In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J, 2002; 21:6820-6831.
52. Waltregny D, Glenisson W, Tran SL, North BJ, Verdin E, Colige A, and Castronovo V: Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J, 2005; 19:966-968.